FibroGen Reports Third Quarter 2023 Financial Results Forward-Looking Statements This presentation contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding the development and commercialization of the company’s product candidates, the potential safety and efficacy profile of its product candidates, and its clinical programs. These forward-looking statements include, but are not limited to, statements under the caption “Upcoming Milestones” ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) Delaware 77-0357827 (State or Other Jurisdictio ...

FibroGen, Inc. (NASDAQ:FGEN) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants David DeLucia - Head of Corporate FP&A / Investor Relations Enrique Conterno - Chief Executive Officer Thane Wettig - Interim Chief Executive Officer Juan Graham - Chief Financial Officer Chris Chung - Senior Vice President of China Operations Mark Eisner - Chief Medical Officer John Hunter - Chief Scientific Officer Conference Call Participants Jason Gerberry - Bank of America Annabel Samimy - Stife ...

业绩总结 - FibroGen在2023年第二季度报告中指出，中国市场Roxadustat销售额达到了7.64亿美元，同比增长44%[17] - 预计公司在未来几个季度将逐步提高运营费用节省，从2023年第三季度开始实现每季度约25-30百万美元的节省[26] 新产品和新技术研发 - Pamrevlumab是一种针对CTGF的mAb，具有潜在的疾病修饰机制，具有重大的商业潜力[4] - FG-3246是一种针对mCRPC和其他实体肿瘤的ADC，具有45%的PSA50响应率和19%的ORR[22] - FG-3165是一种针对免疫肿瘤的抗Gal9抗体，计划在2024年第一季度进行IND[24] - FG-3175是一种针对免疫肿瘤的抗CCR8抗体，计划在2024年下半年进行IND[25] 市场扩张和并购 - Pamrevlumab在胰腺癌治疗中具有巨大商业机会，预计净收入机会超过10亿美元[15] - Roxadustat在ESA+HIF市场中维持领先地位，占据了销售额的45%份额[18] 未来展望 - Pamrevlumab在胰腺癌的LAPC阶段3研究中，主要终点为总生存期，预计在2024年第一季度公布顶线数据[13] - Pamrevlumab在胰腺癌的Precision Promise研究中采用自适应平台试验，主要终点为总生存期，预计能够提供更快的答案[14] - FG-3246的临床研究包括单药物剂量递增和扩展安全性研究，预计在2024年初获得结果[23]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) Delaware 77-0357827 (State or Other Jurisdiction of ...

FibroGen, Inc. (NASDAQ:FGEN) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Michael Tung - Vice President, Corporate Strategy & Investor Relations Enrique Conterno - Chief Executive Officer Juan Graham - Chief Financial Officer Mark Eisner - Chief Medical Officer John Hunter - Chief Scientific Officer Conference Call Participants Jason Gerberry - Bank of America Andy Hsieh - William Blair Danielle Brill - Raymond James Paul Choi - Goldman Sachs Michael Yee - Jefferies Annabel S ...

公司基本信息 - 公司总部位于美国加利福尼亚州旧金山，拥有中国北京和上海的子公司[118] 财务表现 - 2023年第一季度营收为36,161千美元，较去年同期下降40.5%[122] - 2023年第一季度净亏损为76,705千美元，较去年同期增加21.2%[122] - 现金及现金等价物为188,550千美元，较去年同期增加21.0%[122] 产品发展 - Roxadustat在中国市场的销售量在2023年第一季度相比去年同期增长超过50%[140] - Pamrevlumab针对IPF、LAPC和DMD的Phase 3临床试验数据将于2023年中期至2024年中期陆续公布[127] - Roxadustat在中国的化疗诱导性贫血的Phase 3临床试验数据将于2023年第二季度公布[128] - Roxadustat治疗MDS贫血的临床试验未达到主要疗效终点，47.5%的患者在首个28周内实现红细胞输注独立，相比于安慰剂组的33.3%[142] - 2023年第二季度预计发布Roxadustat在化疗诱导贫血方面的临床试验顶线数据[143] 财务合作与收购 - 2023年4月29日与Morgan Stanley Tactical Value签订了7500万美元的融资协议[144] - 2023年5月5日签署了收购Fortis Therapeutics的独家许可和选择权协议[146] - 若行使对Fortis的收购选择权，将支付8000万美元，并可能支付高达2亿美元的与各种监管批准相关的潜在支付[148] 财务状况 - 2023年3月31日，许可收入下降了16590万美元，同比下降73%[162] - 2023年3月31日，产品收入净额为24161万美元，同比增长28%[162] - 2023年3月31日，药品产品收入为2109万美元，同比下降72%[162] 合作协议 - 通过与Astellas和AstraZeneca的合作协议，公司依赖于资金支持进行Roxadustat的研发、生产和商业化[151] - 通过与Astellas和AstraZeneca的合作协议，公司截至2023年3月31日已获得总计1306293万美元的现金收入，以及1237000万美元的潜在现金收入[161]

FibroGen, Inc. Corporate Presentation March 2023 Forward-Looking Statements This presentation contains "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, business strategy, and plans, and objectives of management for future operations, are forward looking statements. These forward-looking statements can generally be identified by ...

FibroGen, Inc. (NASDAQ:FGEN) Q4 2022 Earnings Conference Call February 27, 2023 5:00 PM ET Company Participants Michael Tung - VP of Corporate Strategy and IR Enrique Conterno - CEO Mark Eisner - Chief Medical Officer Juan Graham - CFO Thane Wettig - Chief Commercial Officer Conference Call Participants Andrew Tsai - Jefferies Jason Gerberry - Bank of America Andy Hsieh - William Blair Danielle Brill - Raymond James Yaron Werber - Cowen Annabel Samimy - Stifel Operator Thank you for standing by, and welcome ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) Delaware 77-0357827 (State or other jurisdiction of in ...